Literature DB >> 22461697

CD47(high) expression on CD4 effectors identifies functional long-lived memory T cell progenitors.

Vu Quang Van1, Marianne Raymond, Nobuyasu Baba, Manuel Rubio, Keiko Wakahara, Santos A Susin, Marika Sarfati.   

Abstract

T cell memory is the hallmark of adaptive immunity. Central questions are to determine which cells among proliferating effector T cells will live beyond the crash of the immune response (IR) and develop into functional memory T cells. CD47, considered as a marker of self, is implicated in cell death, cell elimination, and in the inflammatory response. We report in this article that CD47 expression was transiently regulated on Ag-specific CD4 T cells, that is, from CD47(high) to CD47(low) to CD47(high), during the course of the in vivo IR. Specifically, CD47(high) status marked central memory CD4 T cell precursors at an early time point of the IR. By contrast, cytokine production was a functional attribute restricted to CD47(high), but not CD47(low), polyclonal effector CD4 T cells during recall responses in an experimental model of chronic airway inflammatory disease. Passive transfer of CD47(high), but not CD47(low), CD4 T cells in nonlymphopenic naive mice generated long-lived memory T cells capable of anamnestic responses. We conclude that CD47(high) status on CD4 T cells identifies functional long-lived memory T cell progenitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461697     DOI: 10.4049/jimmunol.1102702

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

Review 2.  CD47/SIRPα axis: bridging innate and adaptive immunity.

Authors:  Anneloes van Duijn; Sjoerd H Van der Burg; Ferenc A Scheeren
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

3.  CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice.

Authors:  Vu Quang Van; Nobuyasu Baba; Manuel Rubio; Keiko Wakahara; Benoit Panzini; Carole Richard; Genevieve Soucy; Denis Franchimont; Genevieve Fortin; Ana Carolina Martinez Torres; Lauriane Cabon; Santos Susin; Marika Sarfati
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

4.  Endothelial SIRPα signaling controls VE-cadherin endocytosis for thymic homing of progenitor cells.

Authors:  Boyang Ren; Huan Xia; Yijun Liao; Hang Zhou; Zhongnan Wang; Yaoyao Shi; Mingzhao Zhu
Journal:  Elife       Date:  2022-05-05       Impact factor: 8.713

Review 5.  CD47 as a promising therapeutic target in oncology.

Authors:  Hai Zhao; Shuangshuang Song; Junwei Ma; Zhiyong Yan; Hongwei Xie; Ying Feng; Shusheng Che
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

6.  Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.

Authors:  Erica V Stein; Thomas W Miller; Kelly Ivins-O'Keefe; Sukhbir Kaur; David D Roberts
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

7.  Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Authors:  Andrew S Flies; Nicholas B Blackburn; Alan Bruce Lyons; John D Hayball; Gregory M Woods
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

Review 8.  The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes.

Authors:  Robert C Sharp; Matthew E Brown; Melanie R Shapiro; Amanda L Posgai; Todd M Brusko
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 8.786

9.  Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.

Authors:  Huanpeng Chen; Yuying Yang; Yuqing Deng; Fengjiao Wei; Qingyu Zhao; Yongqi Liu; Zhonghua Liu; Bolan Yu; Zhaofeng Huang
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.